2387505-78-2

2387505-78-2 structure

Name: Calhex 231 hydrochloride
Chemical Name: Calhex 231 hydrochloride
CAS Number: 2387505-78-2
Molecular Formula: C₂₅H₂₈Cl₂N₂O
Molecular Weight: 443.41
Catalog: Signaling Pathways GPCR/G Protein CaSR
Create Date: 2020-06-01 21:42:21
Modify Date: 2025-08-25 12:02:54
Calhex 231 hydrochloride is a CaSR inhibitor via negative allosteric modulation. Calhex 231 hydrochloride blocks Ca2+-induced accumulation of [3H]inositol phosphate with an IC50 of 0.39 μM in HEK293 cells. Calhex 231 hydrochloride has the potential for diabetic cardiomyopathy (DCM) treatment[1][2].

Name	Calhex 231 hydrochloride

Description	Calhex 231 hydrochloride is a CaSR inhibitor via negative allosteric modulation. Calhex 231 hydrochloride blocks Ca2+-induced accumulation of [3H]inositol phosphate with an IC50 of 0.39 μM in HEK293 cells. Calhex 231 hydrochloride has the potential for diabetic cardiomyopathy (DCM) treatment[1][2].
Related Catalog	Research Areas >> Metabolic Disease Signaling Pathways >> GPCR/G Protein >> CaSR
Target	CaSR[1] IC50: 0.39 μM (Inositol phosphate)[2]
In Vitro	Calhex 231 treatment significantly decreases the proliferation of cardiac fibroblasts[1]. Calhex 231 treatment significantly downregulates the CaSR, α-SMA, Col-I/III, MMP2/9 expresses. Calhex231 alleviates high glucose-induced myocardial fibrosis in cardiac fibroblasts[1]. Calhex 231 could inhibit Itch (atrophin-1 interacting protein 4)-ubiquitin proteasome and TGF-β1/Smads pathways, and then depress the proliferation of cardiac fibroblasts, along with the reduction deposition of collagen, alleviate glucose-induced myocardial fibrosis[1]. Cell Proliferation Assay[1] Cell Line: Primary neonatal rat cardiac fibroblasts (CFs) Concentration: 3 µM Incubation Time: 24 hours Result: Significantly decreased the proliferation of cardiac fibroblasts. Western Blot Analysis[1] Cell Line: Primary neonatal rat cardiac fibroblasts (CFs) Concentration: 3 µM Incubation Time: 48 hours Result: The expression of CaSR, α-SMA, Col-I/III, MMP2/9 were significantly downregulated.
In Vivo	Calhex 231 (4.07 mg/kg (10 µmol/kg); intraperitoneal injection; daily; for 12 weeks; male Wistar rats) treatment ameliorates diabetic myocardial fibrosis in type 1 diabetic model (T1D) rats[1]. Animal Model: Male Wistar rats (8 weeks old) injected with Streptozotocin[1] Dosage: 4.07 mg/kg (10 µmol/kg) Administration: Intraperitoneal injection; daily; for 12 weeks Result: Ameliorated diabetic myocardial fibrosis in T1D rats.
References	[1]. Yuan H, et al. Calhex231 Alleviates High Glucose-Induced Myocardial Fibrosis via Inhibiting Itch-Ubiquitin Proteasome Pathway in Vitro. Biol Pharm Bull. 2019 Aug 1;42(8):1337-1344. [2]. Petrel C1, et al. Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca(2+)-sensing receptor. J Biol Chem. 2003 Dec 5;278(49):49487-94.

Molecular Formula	C₂₅H₂₈Cl₂N₂O
Molecular Weight	443.41

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

2387505-78-2	88813-36-9
652973-93-8	7400-27-3
6119-47-7	7716-59-8
7436-22-8	7437-54-9
7524-52-9	7673-07-6
2121513-60-6	2034619-43-5
1337018-52-6	1420863-52-0
1421046-88-9	1421024-58-9
1420847-35-3	1420960-27-5
1420986-67-9	1420856-70-7